Advances in Cancer Research

Advances in Cancer Research

1st Edition - March 15, 2018

Write a review

  • Editors: Kenneth Tew, Paul Fisher
  • eBook ISBN: 9780128151280
  • Hardcover ISBN: 9780128151273

Purchase options

Purchase options
DRM-free (EPub, PDF, Mobi)
Available
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

Advances in Cancer Research, Volume 138, the latest release in this ongoing, well-regarded serial provides invaluable information on the exciting and fast-moving field of cancer research. This volume presents original reviews on research bridging oncology and gene expression, with this volume covering unconventional approaches to modulating the immunogenicity of tumor cells, tumor dormancy and immunoediting, the emerging role of anti-apoptotic Bcl-2 family proteins in chemoresistance, Beclin-1 and autophagy, MDA-7/IL-24, and nanotechnology and medicine.

Key Features

  • Provides information on cancer research
  • Offers outstanding and original reviews on a range of cancer research topics
  • Serves as an indispensable reference for researchers and students alike

Readership

Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology

Table of Contents

  • 1. Leveraging Epigenetics to Enhance the Cellular Response to Chemotherapies and Improve Tumor Immunogenicity
    Liliya Tyutyunyk-Massey, Syed Haqqani, Reshma Mandava, Kirubel Kentiba, Mallika Dammalapati, Nga Dao, Joshua Haueis, David Gewirtz and Joseph W. Landry
    2. VDAC Regulation: A Mitochondrial Target to Stop Cell Proliferation
    Diana Fang and Eduardo N. Maldonado
    3. Acquired Resistance to Drugs Targeting Tyrosine Kinases
    Steven A. Rosenzweig
    4. Extracellular Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes
    Scott T. Eblen
    5. Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases
    Mitchell E. Menezes, Praveen Bhoopathi, Anjan K. Pradhan, Luni Emdad, Swadesh K. Das, Chunqing Guo, Xiang-Yang Wang, Devanand Sarkar and Paul B. Fisher
    6. Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics
    Jesse J. McClure, Xiaoyang Li and C. James Chou
    7. Prospects of Gene Therapy to Treat Melanoma
    Mitchell E. Menezes, Sarmistha Talukdar, Stephen L. Wechman, Swadesh K. Das, Luni Emdad, Devanand Sarkar and Paul B. Fisher

Product details

  • No. of pages: 248
  • Language: English
  • Copyright: © Academic Press 2018
  • Published: March 15, 2018
  • Imprint: Academic Press
  • eBook ISBN: 9780128151280
  • Hardcover ISBN: 9780128151273

About the Serial Volume Editors

Kenneth Tew

Kenneth Tew
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA

The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.

Affiliations and Expertise

Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA

Paul Fisher

Paul Fisher
Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).

Affiliations and Expertise

Professor and Chairman, Department of Human and Molecular Genetics, Institute of Molecular Medicine, Virginia Commonwealth University, VA, USA

Ratings and Reviews

Write a review

There are currently no reviews for "Advances in Cancer Research"